HHS Drops Final Rule on Drug Price Transparency, Dr. Oz Launches Prior Authorization Overhaul — Effective October 1
The Trump administration has finalized a rule giving doctors and patients real-time prescription drug pricing access, effective October 1, 2025. Simultaneously, CMS Administrator Dr. Oz is rolling out a broader coalition to digitize and streamline prior authorizations end-to-end. These are concrete regulatory moves — not press releases — and mainstream coverage is largely sleeping on both.
What Just Changed The Trump administration dropped a final rule on September 2, 2025, that mandates real-time prescription drug price information be available to doctors and patients at the point of care, according to HHS.gov. Effective October 1 , certified health IT systems must enable providers to submit prior authorizations electronically, compare drug prices, view out-of-pocket costs, and see coverage details before a prescription is even written. This is a finalized rule, not a pilot program. It affects Medicare Advantage, Medicaid Managed Care, Medicare Part D, Health Insurance Marketplace, and commercial plans. Dr. Oz Is Moving Fast on Prior Auth Separate from the pricing rule, CMS Administrator Dr. Mehmet Oz published a blog post on May 5, 2026, announcing a major expansion of the prior authorization reform effort — this time pulling in hospitals, health systems, physician practices, EHR vendors, and digital health developers into a unified coalition. The original pledge — announced in June 2025 following a roundtable with RFK Jr., Oz, Medicare Director Chris Klomp, and major insurers covering nearly eight in ten Americans — secured six key commitments from health insurers to cut red tape. That first round already showed results. According to CMS, leading health plans eliminated 11% of prior authorizations across a range of medical services — 6.5 million fewer prior auth requests for patients. One large national plan committed to eliminating authorization requirements for 30% of healthcare services . The new coalition goes further: committed working groups will now align on electronic prior authorization standards across the entire care delivery chain. The stated goal is making electronic prior auth work end-to-end, on time, for every patient. The Numbers Behind the Bureaucratic Nightmare According to CMS, completing prior authorizations currently costs health care providers $20 to $50 per hour and consumes an average of 13 hours per week per provider. That works out to nearly $34,000 and 700 hours per year — per provider — wasted on paperwork instead of patient care. The costs have accumulated over years while both parties have pledged to address the problem. A Drug Pricing Rule Is Coming Too Oz also signaled a separate, forthcoming CMS rule on drug cost transparency during an event hosted by Transparency Rx, according to Healthcare Dive. "If we can do this in an effective way — and we'll have a rule on this by the end of the year, we hope — then we'll be able to very forcefully go after folks who are not transparently sharing what it actually costs," Oz said. The target is clear: pharmacy benefit managers, or PBMs — the powerful middlemen who negotiate drug prices and treat the resulting "net prices" as proprietary secrets. Matt Fiedler, a senior fellow at the Brookings Institution's Center on Health Policy, told Healthcare Dive it's "entirely possible" the administration moves toward forcing disclosure of net drug prices — something the first Trump term attempted and lost in court after a lawsuit from the PCMA, the biggest PBM lobby. The administration hasn't specified whether this new rule is designed to survive that legal challenge. Bipartisan Cover Is Forming According to Axios, Democratic Senator Peter Welch of Vermont said he would back Trump's Most Favored Nation drug pricing approach — meaning Senate Democrats are running out of clean political reasons to oppose this. MFN pricing would tie what Medicare pays for drugs to the lowest price any wealthy nation pays. Pharma opposes it. Voters support it. And now it has a Democrat on record in support. What Mainstream Media Is Getting Wrong Most coverage of Trump's drug pricing push has fixated on the headline $529 billion savings number from the previous 17-deal announcement. That's old news. What's NOT getting covered adequately: the finalized October 1 rule is a structural shift in how prescribing actually works — not a negotiation, not a promise, not a press conference. It's done. The prior authorization coalition also isn't getting the attention it deserves. Six and a half million fewer prior auth requests already eliminated is a real-world result that happened quietly while the media was focused on pharma CEOs testifying on the Hill. Left-leaning outlets are grudgingly covering the pricing push while continuing to frame Oz as a celebrity quack. Right-leaning outlets are cheering without asking hard questions about enforcement mechanisms or whether the forthcoming PBM transparency rule will survive litigation. What This Means for Regular Americans Starting October 1, your doctor will — for the first time — be able to see your drug costs and prior authorization requirements in real time, before writing a prescription. That alone could save millions of people from the pharmacy counter surprise of learning their insurance won't cover a treatment their doctor already ordered. The prior auth overhaul, if it holds,
Read on Unbiased Headlines
